Mendus AB (publ) (IMMU) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Now I will hand the conference over to the speakers, CEO Eric Manting and CFO Lotta Firm. Please go ahead. Good afternoon, everybody. Good morning for those of you from the US joining, and welcome to the Q3 financial business update from Mendes. Public company, we have to show our disclaimer. It's also available on our website. The Q3 of 2025 has mainly been focusing on the progress in myeloid blood cancers. It means we have followed up our advanced to phase two A trial and have indicated a positive outcome now at 48 months median follow up. But also those data give us a lot of confidence about the potential of the product in the broader AML setting. We have started and the trial is ongoing and recruiting. the AMLM22 cadence trial together with the oscillation leukemia lymphoma group in short cadence trial. And this is a phase two B combination trial with a drug approved for AML patients that have been treated with high intensity chemotherapy called oral azacytidine. The trial is gaining momentum and we have set a goal to enroll 20 patients by the first quarter of 2026, after which we will also prepare an initial readout. Another important step is that the AML first-line treatment landscape is evolving, and we have to adapt to that. So next to high-intensity chemotherapy, there's now a very successful regime of two drugs called venetoclax and azacitidine used as a means to get chemo-ineligible AML patients into complete remission, and that is a growing patient population. which is also in a very high need of post-remission immunotherapy. And we want to be able to be part of that transformation of the AML landscape. So we are now preparing with Andrew Wei, the same professor who is also heading the AMLM22 cadence trial, a trial called DIVA, which is a phase one trial ...